• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哮喘中的生物制剂:实现临床缓解的潜力。

Biologics in Asthma: Potential to Achieve Clinical Remission.

机构信息

Division of Allergy and Immunology, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.

Division of Allergy and Immunology, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.

出版信息

Immunol Allergy Clin North Am. 2024 Nov;44(4):725-736. doi: 10.1016/j.iac.2024.08.004. Epub 2024 Sep 6.

DOI:10.1016/j.iac.2024.08.004
PMID:39389720
Abstract

Establishing a universal definition for asthma remission has the potential to improve asthma outcomes and advance research. However, there is still no consensus definition despite broad multidisciplinary efforts to achieve this goal. This study explores the evolving concept of asthma remission, emphasizing the potential of biologics to achieve this state. We will discuss various proposed definitions of asthma remission, international guidelines, and studies evaluating the effectiveness of biologics at achieving clinical remission. We highlight the need for a consensus definition of asthma remission to standardize treatment goals and improve patient outcomes.

摘要

为哮喘缓解建立一个通用的定义有可能改善哮喘的结局并推动研究的进展。然而,尽管进行了广泛的多学科努力来实现这一目标,但仍然没有达成共识的定义。本研究探讨了哮喘缓解的不断发展的概念,强调了生物制剂实现这一状态的潜力。我们将讨论各种提出的哮喘缓解定义、国际指南以及评估生物制剂在实现临床缓解方面的有效性的研究。我们强调需要达成一个哮喘缓解的共识定义,以标准化治疗目标并改善患者的结局。

相似文献

1
Biologics in Asthma: Potential to Achieve Clinical Remission.哮喘中的生物制剂:实现临床缓解的潜力。
Immunol Allergy Clin North Am. 2024 Nov;44(4):725-736. doi: 10.1016/j.iac.2024.08.004. Epub 2024 Sep 6.
2
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.特泽泊单抗对比美泊利珠单抗、贝那利珠单抗和度普利尤单抗治疗嗜酸性粒细胞性哮喘的疗效:一项贝叶斯网络荟萃分析。
J Allergy Clin Immunol. 2023 Mar;151(3):747-755. doi: 10.1016/j.jaci.2022.11.021. Epub 2022 Dec 17.
3
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis.生物制剂治疗的重度哮喘患者的临床缓解达成情况、定义及相关因素:一项系统评价和荟萃分析
Lancet Respir Med. 2025 Jan;13(1):23-34. doi: 10.1016/S2213-2600(24)00293-5. Epub 2024 Nov 14.
4
The role of biologics in inducing remission in asthma.生物制剂在诱导哮喘缓解中的作用。
Ann Allergy Asthma Immunol. 2025 Jan;134(1):19-30. doi: 10.1016/j.anai.2024.09.021. Epub 2024 Oct 9.
5
Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma.生物制剂治疗中重度哮喘的真实世界研究。
Immunol Allergy Clin North Am. 2024 Nov;44(4):737-750. doi: 10.1016/j.iac.2024.07.007.
6
Spanish Consensus on Remission in Asthma (REMAS).西班牙哮喘缓解共识(REMAS)。
Arch Bronconeumol. 2024 Aug;60(8):503-509. doi: 10.1016/j.arbres.2024.04.002. Epub 2024 Apr 23.
7
Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.生物制剂在降低哮喘相关住院率方面的疗效比较差异较小,而在总体恶化方面则较大。
J Allergy Clin Immunol Pract. 2024 Jun;12(6):1568-1574.e2. doi: 10.1016/j.jaip.2024.02.034. Epub 2024 Feb 29.
8
When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.美泊利珠单抗和度匹鲁单抗序贯治疗重度特应性嗜酸性粒细胞性哮喘质疑嗜酸性粒细胞在介导疾病临床表型中的作用:病例报告。
J Med Case Rep. 2024 Jan 31;18(1):63. doi: 10.1186/s13256-023-04255-8.
9
Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.生物制剂用于口服糖皮质激素依赖型哮喘的疗效与安全性:一项系统评价和网状Meta分析
J Allergy Clin Immunol Pract. 2024 Feb;12(2):409-420. doi: 10.1016/j.jaip.2023.11.007. Epub 2023 Nov 14.
10
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.美泊利单抗治疗重度嗜酸性粒细胞性哮喘的长期临床疗效及持续缓解:REMI-M研究
J Allergy Clin Immunol Pract. 2024 Dec;12(12):3315-3327. doi: 10.1016/j.jaip.2024.08.033. Epub 2024 Aug 27.